JPMORGAN CHASE & CO - OCULAR THERAPEUTIX INC ownership

OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 141 filers reported holding OCULAR THERAPEUTIX INC in Q3 2021. The put-call ratio across all filers is 0.59 and the average weighting 0.8%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of OCULAR THERAPEUTIX INC
ValueSharesWeighting
Q3 2023$213,134
-35.6%
67,877
+5.9%
0.00%
Q2 2023$330,813
-1.8%
64,111
+0.3%
0.00%
Q1 2023$337,000
+259130.8%
63,941
+38.7%
0.00%
Q4 2022$130
-99.9%
46,103
-3.0%
0.00%
Q3 2022$198,000
+11.2%
47,547
+7.5%
0.00%
Q2 2022$178,000
-20.5%
44,227
-2.3%
0.00%
Q1 2022$224,000
-12.8%
45,254
+22.9%
0.00%
Q4 2021$257,000
-24.4%
36,815
+8.1%
0.00%
Q3 2021$340,000
-27.8%
34,067
+2.6%
0.00%
Q2 2021$471,000
-28.7%
33,199
-17.6%
0.00%
Q1 2021$661,000
-61.0%
40,304
-50.8%
0.00%
Q4 2020$1,695,000
-4.8%
81,880
-64.1%
0.00%
Q3 2020$1,781,000
+1136.8%
228,038
+1222.4%
0.00%
Q2 2020$144,000
+114.9%
17,244
+27.8%
0.00%
Q1 2020$67,000
+24.1%
13,494
-0.7%
0.00%
Q4 2019$54,000
+31.7%
13,5930.0%0.00%
Q3 2019$41,000
-96.8%
13,593
-95.4%
0.00%
Q2 2019$1,295,000
+1750.0%
292,947
+1560.7%
0.00%
Q1 2019$70,000
+105.9%
17,640
+106.8%
0.00%
Q4 2018$34,000
-90.6%
8,530
-83.8%
0.00%
Q3 2018$362,000
-28.9%
52,664
-30.3%
0.00%
Q2 2018$509,000
+1239.5%
75,512
+1200.8%
0.00%
Q1 2018$38,000
-68.1%
5,805
-78.4%
0.00%
Q4 2017$119,000
-94.4%
26,827
-91.9%
0.00%
Q3 2017$2,129,000
-32.2%
332,700
-1.7%
0.00%
-100.0%
Q2 2017$3,138,000
-7.5%
338,500
-7.5%
0.00%0.0%
Q1 2017$3,394,000365,8250.00%
Other shareholders
OCULAR THERAPEUTIX INC shareholders Q3 2021
NameSharesValueWeighting ↓
SUMMER ROAD LLC 6,122,089$32,263100.00%
Opaleye Management Inc. 6,105,900$32,178,0939.64%
DELTEC ASSET MANAGEMENT LLC 1,913,612$10,084,7352.49%
Knoll Capital Management, LLC 200,000$1,504,0002.32%
Endurant Capital Management LP 512,744$2,702,1611.39%
Knoll Capital Management, LLC 95,800$504,8660.78%
Covestor Ltd 60,008$3160.28%
Ikarian Capital, LLC 200,000$1,054,0000.24%
EAM Investors, LLC 224,211$1,181,5920.23%
Nebula Research & Development LLC 22,474$118,4380.21%
View complete list of OCULAR THERAPEUTIX INC shareholders